← ANALYST RATINGS · TIPRANKS
Natera (NTRA): analyst forecast and price target
Analyst consensus
Strong Buy16 Buy1 Hold0 Sell
Ratings of 17 analysts in the last 3 months · top analysts only12-month forecast
Based on 17 price targets given in the last 3 months, the average target is $399, the highest $480, the lowest $320. The average is +1.5% from the last price of $393.
Analyst ratings 29
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Casey Woodring★★★★★★★★★★#2489 · hits 62% · avg +8.2% | J.P. Morgan | $360 → $460+27.8% | Buy | +16.9% | Reiterated | 14.10.26on TipRanks 06:10 | +0.9%next day +2.3% | ↗ |
| Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% | TD Cowen | $340 → $480+41.2% | Buy | +22.0% | Reiterated | 13.10.26on TipRanks 08:46 | −0.5%next day +0.9% | ↗ |
| Kallum Titchmarsh★★★★★★★★★★#2647 · hits 58% · avg +9.6% | Morgan Stanley | $355 → $435+22.5% | Buy | +10.6% | Assigned | 12.10.26on TipRanks 09:00 | −0.7%next day −0.5% | ↗ |
| Eve Burstein★★★★★★★★★★#1300 · hits 72% · avg +25.0% | Bernstein | $365 | Buy | −7.2% | Reiterated | 12.10.26on TipRanks 06:30 | −0.7%next day −0.5% | ↗ |
| Luke Sergott★★★★★★★★★★#1255 · hits 49% · avg +9.8% | Barclays | $340 → $475+39.7% | Buy | +20.7% | Reiterated | 07.10.26on TipRanks 03:55 | −1.0%next day −0.8% · 5 days +0.8% | ↗ |
| Patrick B Donnelly★★★★★★★★★★#2106 · hits 54% · avg +6.0% | Citi | $365 → $480+31.5% | Buy | +22.0% | Reiterated | 06.10.26on TipRanks 06:40 | −6.4%next day −1.0% · 5 days −1.1% | ↗ |
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $470 → $481+2.3% | Buy | +22.3% | Reiterated | 06.10.26on TipRanks 05:05 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $455 → $472+3.7% | Buy | +20.0% | Reiterated | 06.10.26on TipRanks 05:05 | — | |
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $445 → $462+3.8% | Hold | +17.4% | Reiterated | 06.10.26on TipRanks 05:05 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $435 → $464+6.7% | Hold | +17.9% | Reiterated | 06.10.26on TipRanks 05:05 | — | |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $470 → $483+2.8% | Buy | +22.8% | Reiterated | 06.10.26on TipRanks 05:05 | — | |
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $429 → $451+5.1% | Hold | +14.6% | Reiterated | 06.10.26on TipRanks 05:05 | — | |
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $473 → $470−0.6% | Buy | +19.5% | Reiterated | 04.10.26on TipRanks Oct 3 23:05 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $459 → $455−0.9% | Buy | +15.6% | Reiterated | 04.10.26on TipRanks Oct 3 23:05 | — | |
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $448 → $445−0.7% | Hold | +13.1% | Reiterated | 04.10.26on TipRanks Oct 3 23:05 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $438 → $435−0.7% | Hold | +10.6% | Reiterated | 04.10.26on TipRanks Oct 3 23:05 | — | |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $473 → $470−0.6% | Buy | +19.5% | Reiterated | 04.10.26on TipRanks Oct 3 23:05 | — | |
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $432 → $429−0.7% | Hold | +9.0% | Reiterated | 04.10.26on TipRanks Oct 3 23:05 | — | |
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $471 → $473+0.4% | Buy | +20.2% | Reiterated | 02.10.26on TipRanks Oct 1 23:05 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $457 → $459+0.4% | Buy | +16.7% | Reiterated | 02.10.26on TipRanks Oct 1 23:05 | — | |
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $447 → $448+0.2% | Hold | +13.9% | Reiterated | 02.10.26on TipRanks Oct 1 23:05 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $436 → $438+0.5% | Hold | +11.3% | Reiterated | 02.10.26on TipRanks Oct 1 23:05 | — | |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $471 → $473+0.4% | Buy | +20.2% | Reiterated | 02.10.26on TipRanks Oct 1 23:05 | — | |
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $430 → $432+0.5% | Hold | +9.8% | Reiterated | 02.10.26on TipRanks Oct 1 23:05 | — | |
| Subbu Nambi★★★★★★★★★★#281 · hits 72% · avg +34.4% | Guggenheim | $360 → $475+31.9% | Buy | +20.7% | Reiterated | 01.10.26on TipRanks 08:35 | −1.3%next day −0.3% · 5 days −5.6% | ↗ |
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $472 → $471−0.2% | Buy | +19.7% | Reiterated | 30.09.26on TipRanks Sep 29 23:05 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $458 → $457−0.2% | Buy | +16.2% | Reiterated | 30.09.26on TipRanks Sep 29 23:05 | — | |
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $448 → $447−0.2% | Hold | +13.6% | Reiterated | 30.09.26on TipRanks Sep 29 23:05 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $437 → $436−0.2% | Hold | +10.8% | Reiterated | 30.09.26on TipRanks Sep 29 23:05 | — | |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $472 → $471−0.2% | Buy | +19.7% | Reiterated | 30.09.26on TipRanks Sep 29 23:05 | — | |
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $431 → $430−0.2% | Hold | +9.3% | Reiterated | 30.09.26on TipRanks Sep 29 23:05 | — | |
| Eve Burstein★★★★★★★★★★#1300 · hits 72% · avg +25.0% | Bernstein | $365 | Buy | −7.2% | Reiterated | 25.09.26on TipRanks Sep 26 08:20 | +0.4%next day +0.6% · 5 days −0.3% | ↗ |
| Luke Sergott★★★★★★★★★★#1255 · hits 49% · avg +9.8% | Barclays | $340 | Buy | −13.6% | Reiterated | 25.09.26on TipRanks 04:45 | +0.4%next day +0.6% · 5 days −0.3% | ↗ |
| Dan Leonard★★★★★★★★★★#656 · hits 62% · avg +14.1% | RBC Capital | $350 → $460+31.4% | Buy | +16.9% | Reiterated | 24.09.26on TipRanks Sep 25 07:30 | +4.7%next day +0.4% · 5 days +0.3% | ↗ |
| Evie Koslosky★★★★★★★★★★#9740 · hits 58% · avg −3.1% | Goldman Sachs | $290 → $375+29.3% | Hold | −4.7% | Reiterated | 20.09.26on TipRanks Sep 21 08:15 | −1.2%next day +5.5% · 5 days +12.1% | ↗ |
| Kallum Titchmarsh★★★★★★★★★★#2647 · hits 58% · avg +9.6% | Morgan Stanley | $355 | Buy | −9.8% | Reiterated | 14.09.26on TipRanks Sep 15 07:15 | +4.4%next day +3.1% · 5 days +6.5% | ↗ |
| Doug Schenkel★★★★★★★★★★#216 · hits 65% · avg +26.2% | Wolfe Research | $290 → $435+50.0% | Buy | +10.6% | Reiterated | 09.09.26on TipRanks Sep 14 09:30 | +2.4%next day −0.7% · 5 days +5.6% | ↗ |
| Jamie Clark★★★★★★★★★★#6680 · hits 75% · avg +5.9% | Rothschild & Co Redburn | $385 | Buy | −2.1% | Initiated | 08.09.26on TipRanks 05:20 | −0.7%next day +2.4% · 5 days +9.3% | ↗ |
| David Westenberg★★★★★★★★★★#602 · hits 56% · avg +17.3% | Piper Sandler | $364 | Buy | −7.6% | Reiterated | 24.08.26on TipRanks 08:15 | −1.0%next day +2.4% · 5 days −2.2% | ↗ |
| Tycho Peterson★★★★★★★★★★#1097 · hits 57% · avg +9.8% | Jefferies | $330 | Buy | −16.1% | Reiterated | 17.08.26on TipRanks 11:16 | +1.8%next day −0.1% · 5 days +5.5% | ↗ |
| Name not given | — | $315 → $365+15.9% | Buy | −7.2% | Reiterated | 14.08.26on TipRanks 06:55 | −0.1%next day +1.8% · 5 days +8.5% | ↗ |
| Unknown Analyst | Stephens | $350 | Buy | −11.0% | Reiterated | 12.08.26on TipRanks Aug 14 06:55 | +0.8%next day −2.3% · 5 days +3.3% | ↗ |
| Matt Larew★★★★★★★★★★#816 · hits 63% · avg +19.3% | William Blair | — | Buy | — | Reiterated | 07.08.26on TipRanks 13:15 | +20.8%next day −1.1% · 5 days −4.2% | ↗ |
| Daniel Markowitz CFA★★★★★★★★★★#1752 · hits 61% · avg +22.3% | Evercore ISI | $300 → $360+20.0% | Buy | −8.5% | Reiterated | 07.08.26on TipRanks 08:45 | +20.8%next day −1.1% · 5 days −4.2% | ↗ |
| Catherine Ramsey Schulte★★★★★★★★★★#864 · hits 53% · avg +11.2% | Robert W. Baird | $379 → $348−8.2% | Buy | −11.5% | Reiterated | 07.08.26on TipRanks 08:10 | +20.8%next day −1.1% · 5 days −4.2% | ↗ |
| Kyle Mikson CFA★★★★★★★★★★#2814 · hits 38% · avg +5.9% | Canaccord Genuity | $330 → $375+13.6% | Buy | −4.7% | Reiterated | 07.08.26on TipRanks 07:40 | +20.8%next day −1.1% · 5 days −4.2% | ↗ |
| Mark Massaro★★★★★★★★★★#2635 · hits 40% · avg +5.7% | BTIG | $290 → $320+10.3% | Buy | −18.7% | Reiterated | 07.08.26on TipRanks 07:00 | +20.8%next day −1.1% · 5 days −4.2% | ↗ |
| Puneet Souda★★★★★★★★★★#2942 · hits 45% · avg +4.1% | Leerink Partners | $280 → $330+17.9% | Buy | −16.1% | Reiterated | 07.08.26on TipRanks 06:55 | +20.8%next day −1.1% · 5 days −4.2% | ↗ |
| Casey Woodring★★★★★★★★★★#2489 · hits 62% · avg +8.2% | J.P. Morgan | $315 → $360+14.3% | Buy | −8.5% | Reiterated | 07.08.26on TipRanks 06:55 | +20.8%next day −1.1% · 5 days −4.2% | ↗ |
| Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% | TD Cowen | $325 → $340+4.6% | Buy | −13.6% | Assigned | 07.08.26on TipRanks 00:32 | +20.8%next day −1.1% · 5 days −4.2% | ↗ |
| William Bonello★★★★★★★★★★#152 · hits 66% · avg +35.0% | Craig-Hallum | — | Buy | — | Reiterated | 09.07.26on TipRanks 12:35 | +1.9%next day −4.7% · 5 days −4.1% | ↗ |
| Paige Chamberlain★★★★★★★★★★#7338 · hits 100% · avg +13.9% | Wolfe Research | $275 → $260−5.5% | Buy | −33.9% | Assigned | 01.06.26on TipRanks Jun 3 00:15 | −2.3%next day −2.9% · 5 days +0.1% | ↗ |
| Navann Ty★★★★★★★★★★#4487 · hits 56% · avg +7.4% | Exane BNP Paribas | $172 | Hold | −56.3% | Upgrade | 27.10.25on TipRanks 09:15 | −1.3%next day −1.6% · 5 days +3.4% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Natera
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $370 at a price of $413 (−10.5%); now: $400 at $393 (+1.7%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Buy | 18 | 23 | 28 | 34 | 31 | 28 |
| Hold | 1 | 3 | 5 | 5 | 5 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.27 (from $-0.61 to $0.13). Last quarter: $-0.47.
Sales
Next quarter’s sales estimate — $708M (from $677M to $720M). Last quarter: $753M.
Best top-analyst consensus in the sector · Healthcare
About Natera
- CEO: Steven Leonard Chapman
- Employees: 6,138
- 13011 McCallen Pass Building A, Austin, TX, 78753, US
- www.natera.com
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded
Data from the stock’s TipRanks forecast page, read 21 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗